Philadelphia chromosome
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
... Abstract: Chronic myelogenous leukemia (CML) is a pluripotent stem cell disease characterized by the presence of the Philadelphia chromosome and the bcr-abl gene. The discovery of tyrosine kinase inhibitors ...
9
Neurological Complications of Myeloproliferative Syndromes with Negative Philadelphia Chromosome (MPS Ph-) in Lome Tertiary Hospital
... Komi Assogba, Kodzo Vinyo Kumako, Kossivi Martin Apetse, Essohana Justin Padaro, Abago Balaka, Abdoullaye Idrissou, Komi Igneza Agbotsou, Nyenèvi Komla Anayo, Abdullah Blakime, Agnon Ayélola Koffi Balogou. Neurological ...
5
A novel <em>BCR-ABL1</em> mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
... The Philadelphia chromosome (Ph) is the most frequent genetic abnormality in adult ALL (Ph + ALL), representing 20%–30% of the B-lineage cases (B-ALL) but only 5% of the pediatric ...
10
Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
... refractory Philadelphia chromosome-negative ALL treated with non-VSLI single agents, only 4% achieved complete remission/CRi, with 17 of 56 patients dying within 30 days of ...
10
Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome positive chronic myelogenous leukemia (CML) Amplification of rearranged c abl oncogenes in CML blast crisis
... 20 Philadelphia chromosome (Ph1) positive chronic myelogenous leukemia (CML) samples by Southern blot hybridization to determine the location of the breakpoints that occur on chromosomes 9 and 22 in the Ph1 ...
6
The Philadelphia chromosome in leukemogenesis
... Ph: Philadelphia chromosome; CML: chronic myeloid leukemia; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; MPAL: mixed‑pheno‑ type acute leukemia; TK: tyrosine kinase; TKIs: tyrosine kinase ...
15
Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
... a Philadelphia chromosome positive acute myeloid leukemia, detecting the cytogenetic aberration; t(9;22)(q34;q22) encoding the rare BCR-ABL1 fusion gene; ...to Philadelphia chromosome positive ...
8
ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells
... A major drawback of tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is that primitive CML cells are able to survive TKI-mediated BCR-ABL inhibition, leading to disease persistence in patients. ...
14
Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
... +: Philadelphia chromosome-positive; RIC: Reduced-intensity conditioning; RQ-PCR: Real-time quantitative reverse transcription-polymerase chain reac- tion; SCT: Stem cell transplantation; TFR: ...
14
PHILADELPHIA CHROMOSOME IN PRETHERAPEUTIC CASES OF CHRONIC MYELOGENOUS LEUKEMIA
... This Table 1 shows the incidence of philadelphia chromosome in clinically and pathologically diagnosed CML patients. In the present study 89 cases of clinically and pathologically diagnosed patients were ...
15
Applying the discovery of the Philadelphia chromosome
... the Philadelphia chromosome in cells from individuals with chronic myelogenous leukemia (CML) led to the recognition that the BCR-ABL tyrosine kinase causes ...
9
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
... the Philadelphia chromosome in the CML, the discovery of the JAK2 V617F mutation in 2005 [5,6] is the most thril- ling development in the molecular diagnosis of Ph- negative ...
10
Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China
... Approximately 25–30 % of adults and 3 % of children with acute lymphoblastic leukemia (ALL) express the onco- genic BCR-ABL protein, which results from a 9;22 chromosomal translocation known as the Philadelphia ...
10
Ruxolitinib/nilotinib cotreatment inhibits leukemia propagating cells in Philadelphia chromosome positive ALL
... University Institute of Hematology from January 1, 2015 to May 31, 2015 were enrolled for this in vitro and in vivo study. The patient clinical characteristics are shown in Table 1. The inclusion criteria were (1) 18–60 ...
13
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
... ABL tyrosine kinase inhibitor (TKI) therapy has improved the survival of patients with Philadelphia (Ph) chromosome-positive leukemia. However, ABL TKIs cannot eradicate leukemia stem cells. Therefore, new ...
11
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
... Abstract: Development of BCR-ABL tyrosine kinase inhibitors (TKIs) have improved outcomes for patients diagnosed with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic ...
8
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
... Finally, the Phase III randomized ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Philadelphia Chromosome Positive) trial com- pared im[r] ...
6
Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors
... Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome- positive acute lymphoblastic leukemia from the imatinib to the second- generation tyrosine kinase inhibi[r] ...
8
Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
... Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) follow[r] ...
12
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
... Kantarjian HM, Giles F, Gattermann N, et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhib- itor, is effective in patients with Philadelphia chromosome-[r] ...
6